The biotech company Curevac has developed a corona vaccine that is still awaiting approval. Due to high research costs, the…
Read More »CureVac
The new “mRNA vaccines” are not only considered a major milestone in the fight against the corona pandemic – the…
Read More »
CureVac released new test data on Wednesday for the potential, previously unapproved COVID-19 vaccine CVnCoV. In non-human primates, the vaccine…
Read More »
Bayer stock, a previous “problem child” in the DAX, has performed significantly better since the multi-year low of EUR 39.91…
Read More »Despite the partial lockdown, German industry surprisingly received more orders for the seventh month in a row. New business grew…
Read More »The Bayer deal yesterday brought plenty of momentum to the CureVac share. At the beginning of trading, the US technology…
Read More »Important instructions This document was created by HSBC Trinkaus & Burkhardt AG (“HSBC”). It is for informational purposes only and…
Read More »Yesterday, the CureVac share on the NASDAQ started again on the 50-day line – and as on Monday, the break…
Read More »
On the NASDAQ, the CureVac share failed yesterday’s first attempt to get the biotech stock out of the downward movement…
Read More »Not only the BioNTech share was under significant pressure after a new all-time high in December 2020, but also the…
Read More »